Real-world data from Poland shows that TEER is associated with comparable mortality to other European registries, though heart failure hospitalization rates are higher, likely reflecting a higher-risk patient population.
BACKGROUND: Transcatheter mitral edge-to-edge repair (TEER) is an effective and safe therapeutic option for patients with severe mitral regurgitation (MR) and may be used in the treatment of both primary and secondary MR. AIMS: To provide insights into patients' characteristics, in-hospital procedural outcomes, and 1-year follow-up for 1204 patients with severe MR treated with TEER in Poland. METHODS: A comprehensive, all-comers, administrative database that covers the whole population of Poland was searched for all reimbursed TEER procedures performed since 2019. Electronic health records provided details regarding baseline study group characteristics as well as the in-hospital and 1-year outcomes. RESULTS: The in-hospital mortality was 3.2% with no difference between sexes. Blood transfusion was required in 7.8% of patients, more frequently in women (11.1% vs. 6.1%; P = 0.004). Patients with atrial fibrillation had a higher rate of in-hospital heart failure (HF) in New York Heart Association functional class II-IV vs. I (66.8% vs. 42.5%; P < 0.001). Mean follow-up was 336.7 days. The mortality rate was 13.9% and was comparable between males and females and between patients with and without atrial fibrillation. 54.5% of patients required a HF hospitalization and 65.0% a cardiovascular hospitalization. Mortality was comparable to other European registries, but rates of HF hospitalization were higher in the Polish population. CONCLUSIONS: The Polish TEER registry provides real-world data on transcatheter edge-to-edge repair procedures, demonstrating outcomes comparable to other European registries despite a higher-risk patient population.
WOJAKOWSKI et al. (Wed,) studied this question.